FATE THERAPEUTICS INC
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-136.3M | $-186.3M | $-160.9M | $-281.7M | $-212.2M | $-173.4M | $-98.1M | $-66.6M |
| Depreciation & Amortization | $12.9M | $19.0M | $18.3M | $13.8M | $5.9M | $3.1M | $2.2M | $1.2M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-106.1M | $-122.9M | $-132.3M | $-248.2M | $-162.9M | $-39.2M | $-83.2M | $-38.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.0M | $730.0K | $6.2M | $35.6M | $50.7M | $4.9M | $7.4M | $2.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $111.2M | $12.2M | $112.7M | $166.8M | $-324.0M | $-161.1M | $-157.5M | $-463.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $5.5M | $99.9M | $85.0K | $9.2M | $453.1M | $282.8M | $149.9M | $140.8M |
| Net Change in Cash | $10.6M | $-10.8M | $-19.5M | $-72.3M | $-33.8M | $82.5M | $-90.7M | $101.7M |
| Free Cash Flow | $-112.0M | $-123.6M | $-138.4M | $-283.8M | $-213.6M | $-44.2M | $-90.6M | $-41.0M |